Oxford Corona Vaccine AstraZeneca can be 90 percent effective

New Delhi: The Oxford-AstraZeneca vaccine has an average success rate of 70 per cent from covid-19. However, success varied from 62 to 90 per cent in different doses.

AstraZeneca issued a statement informing it. This is a relief news for India, because the Serum Institute in India is engaged in the production of this vaccine.

AstraZeneca Corona Vaccine 90 percent effective:

At the same time, Serum Institute CEO Adar Poonawala said on Monday. He is very happy that the coviShield vaccine will give people up to 90 percent protection against corona. According to the statement released by Astrazeneca, the corona vaccine was up to 90% effective on patients. According to the results of late-stage tests in the UK and Brazil. During this period, the patient was given half the dose for the first time. And then after about a month it was given as a full dose.

ALSO READ: Corona Vaccine: Vaccination program to start soon as Pfizer gets approval

According to the results, when two doses of this vaccine. It were given to the patient at intervals of one month, it was effective up to 62%. Thus, combined analyzes of these two results show that the vaccine is on average 70% effective.

Adar Poonawala tweeted, "I am happy to hear that the low cost. Also, soon to be widely available Covid-19 vaccine 'Coveshield' is up to 90% effective." Further details on this will be provided this evening.

Let us know that Serum Institute of India. The world's largest vaccine manufacturer, has already manufactured millions of doses of vaccine. Vaccine developed in collaboration with Oxford University.

At the same time, American vaccine maker Pfizer and BioNotech created this vaccine. This vaccine found 95 percent effective on corona patients. Reports said that Pfizer has kept the price of one dose of this drug in the US at $ 20, or about Rs. 1500.

Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on Twitter.